Post by eleva

Meet our Director Lead Discovery Dr. Timo Johannssen at the 29th European Society for the Advancement of Cell Technology (ESACT) Meeting in Salzburg on June 7–10! At Eleva, we are developing previously inaccessible biologic therapeutics using our proprietary moss-based expression platform. Our technology enables precise, human-like glycosylation and unlocks complex proteins that are often out of reach for conventional expression systems. Our pipeline includes recombinant complement regulator Factor H (CPV-104), currently being investigated for complement-mediated diseases, as well as glyco-optimized aGal (RPV-001) for enzyme replacement therapy in Fabry disease. We look forward to scientific discussions on advances in cell technology and next-generation biologics! #ESACT #CellTechnology #Bioprocessing #DrugDevelopment #NextGenBiologics